<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-19T01:08:38Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/11953" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/11953</identifier><datestamp>2026-10-18T20:49:51Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>Host Genetic Polymorphisms and Disease Severity in Pregnant Women with COVID-19 in Türkiye</dc:title><dc:creator>Polat, Seher</dc:creator><dc:creator>Kiremitli, Sevil</dc:creator><dc:creator>Kiremitli, Tunay</dc:creator><dc:creator>Kirkinci, Ahmet</dc:creator><dc:creator>Kurnuç, Fatma Zehra</dc:creator><dc:creator>Arslan, Yusuf Kemal</dc:creator><dc:subject>COVID-19</dc:subject><dc:subject>gene polymorphism</dc:subject><dc:subject>genetic susceptibility</dc:subject><dc:subject>pregnant women</dc:subject><dc:subject>5,10 methylenetetrahydrofolate reductase (FADH2)</dc:subject><dc:subject>angiotensin converting enzyme 2</dc:subject><dc:subject>antibiotic agent</dc:subject><dc:subject>enoxaparin</dc:subject><dc:subject>plasminogen activator inhibitor 1</dc:subject><dc:subject>adult</dc:subject><dc:subject>Article</dc:subject><dc:subject>biochemical analysis</dc:subject><dc:subject>cohort analysis</dc:subject><dc:subject>controlled study</dc:subject><dc:subject>coronavirus disease 2019</dc:subject><dc:subject>disease severity</dc:subject><dc:subject>DNA polymorphism</dc:subject><dc:subject>female</dc:subject><dc:subject>gene frequency</dc:subject><dc:subject>genotype</dc:subject><dc:subject>hospitalization</dc:subject><dc:subject>human</dc:subject><dc:subject>human cell</dc:subject><dc:subject>major clinical study</dc:subject><dc:subject>pregnant woman</dc:subject><dc:subject>risk assessment</dc:subject><dc:subject>Turkey (republic)</dc:subject><dc:description>Objective: The study aimed to analyze the association between coronavirus disease-2019 (COVID-19) disease severity and genetic susceptibility in pregnant women. Material and Methods: The research included 54 pregnant women with confirmed COVID-19 diagnosis. All volunteers were evaluated physically and biochemically. Angiotensin-converting enzyme (ACE)2 (p.T27A A&gt;G, p.G326E G&gt;A, p.K419T A&gt;C, ACE (p.T776T A&gt;G, and g.16471_16472delinsALU (I/D), AGTR1 c.*86A&gt;C, methylenetetrahydrofolate-reductase (MTHFR) p.A222V C&gt;T and PAI-1-844 G&gt;A were analyzed. Results: The allele frequency was also compared with control groups of the different studies made on Turkish women. MTHFR “CT” genotype compared to “CC” had lower platelet counts (p=0.015). In ACE “ID” genotype, there was a lower D-dimer level compared to “DD” genotype (p=0.02). In PAI-1-844G&gt;A, the AA vs. AG+GG genotype and AA vs. GG genotype elevate the risk of hospitalization 6.4-fold (OR: 6.4 95% (Cl): 1.6-25.8 p=0.009), and 4.6-fold (OR: 4.6 95% CI:1.0-21.6 p=0.049), respectively. In MTHFR p.A222V, to have CC vs. CT genotype increased the risk of enoxaparin and antibiotic use 4.1-fold and 3.2-fold at the borderline significance (OR: 4.1 95% Cl: 0.99-16.9 p=0.052 and OR: 3.2 95% Cl: 0.98-10.5 p=0.053), respectively. An allele frequency difference wasn't found between the patient and the healthy women related to the investigated polymorphisms. Conclusion: PAI-1-844G&gt;A, MTHFR p.A222V, and ACE (I/D) associated with a poor COVID-19 outcome, the risk of enoxaparin and antibiotic use, and also increased risk of hospitalization. Allele frequencies of the genes were not different between healthy control women and women with COVID-19; genetic variation may not influence the risk of infection but disease severity. Copyright © 2024 by Türkiye Klinikleri.</dc:description><dc:publisher>OrtadogÂu Reklam Tanitim Yayincilik Turizm Egitim Insaat Sanayi ve Ticaret A.S.</dc:publisher><dc:date>2024</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/11953</dc:identifier><dc:identifier>https://doi.org/10.5336/jcog.2023-96185</dc:identifier><dc:identifier>2619-9467</dc:identifier><dc:language>en</dc:language><dc:relation>Journal of Clinical Obstetrics and Gynecology</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/11953</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>